Stay updated on Pralsetinib in RET+ Cancer Clinical Trial

Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.5.4, replacing the previous Revision: v3.5.3, indicating a minor platform update to the page without changing its content.
    Difference
    0.0%
    Check dated 2026-05-17T10:42:25.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Adds a citation to NCCN Guidelines: Thyroid Carcinoma, Version 1.2025 (J Natl Compr Canc Netw. 2025). This reference provides guideline context for thyroid cancer management without altering the study’s core content.
    Difference
    0.0%
    Check dated 2026-05-10T11:02:38.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    A new final ARROW study article on pralsetinib in RET-altered solid tumors was added to Publications (J Clin Oncol, May 2026) with DOI 10.1200/JCO-25-01489. The previous online-ahead-of-print citation for this article was removed.
    Difference
    0.0%
    Check dated 2026-05-03T01:54:14.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The page’s displayed revision/version in the footer was updated from v3.5.2 to v3.5.3, indicating a technical update to the site interface rather than a change to the trial record.
    Difference
    0.0%
    Check dated 2026-04-25T18:45:41.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    Revision updated to v3.5.2; the previous revision v3.5.0 was removed.
    Difference
    0.0%
    Check dated 2026-04-18T13:36:20.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    Added bibliographic entry: Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer, J Clin Oncol, 2026 (online ahead of print).
    Difference
    0.0%
    Check dated 2026-04-04T05:51:32.000Z thumbnail image

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.